$ESMC
ESCALON MEDICAL CORP Stock $esmc

$esmc Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-K Financial Statement

#000086266822000023 Filed on September 28, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022
Revenue	$2.605M	$2.911M	$10.70M
YoY Change	-2.63%	2.69%	2.21%
Cost Of Revenue	$1.548M	$1.415M	$6.096M
YoY Change	-6.94%	-5.12%	0.86%
Gross Profit	$1.056M	$1.496M	$4.607M
YoY Change	4.47%	11.36%	4.06%
Gross Profit Margin	40.56%	51.39%	43.04%
Selling, General & Admin	$1.108M	$1.231M	$4.086M
YoY Change	22.51%	31.46%	14.44%
% of Gross Profit	104.89%	82.26%	88.69%
Research & Development	$264.2K	$210.0K	$991.0K
YoY Change	-9.25%	-4.93%	11.29%
% of Gross Profit	25.01%	14.04%	21.51%
Depreciation & Amortization	$11.49K	$11.49K	$48.43K
YoY Change	-14.61%	-3.28%	8.08%
% of Gross Profit	1.09%	0.77%	1.05%
Operating Expenses	$1.372M	$1.441M	$5.077M
YoY Change	14.77%	24.51%	13.81%
Operating Profit	-$315.9K	$55.39K	-$470.1K
YoY Change	71.23%	-70.28%	1294.97%
Interest Expense	$4.827K	-$5.360K	$18.41K
YoY Change	2.77%	0.0%	-15.73%
% of Operating Profit		-9.68%
Other Income/Expense, Net	-$4.827K	$0.00	$488.1K
YoY Change	-100.96%	-100.0%	-2763.67%
Pretax Income	-$320.7K	$50.03K	$18.08K
YoY Change	-201.1%	-72.74%	-134.76%
Income Tax			$0.00
% Of Pretax Income			0.0%
Net Earnings	-$320.7K	$50.03K	$18.08K
YoY Change	-201.1%	-72.74%	-134.76%
Net Earnings / Revenue	-12.31%	1.72%	0.17%
Basic Earnings Per Share	-$0.05		$0.00
Diluted Earnings Per Share	-$0.05	$6.747K	$0.00
COMMON SHARES
Basic Shares Outstanding	7.415M shares	7.415M shares	7.415M shares
Diluted Shares Outstanding	7.415M shares		13.22M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$275.2K	$593.9K	$593.9K
YoY Change	-78.09%	-64.03%	-64.03%
Cash & Equivalents	$275.1K	$593.9K	$593.9K
Short-Term Investments
Other Short-Term Assets	$216.5K	$190.0K	$446.2K
YoY Change	10.53%	1.43%	0.66%
Inventory	$1.617M	$1.417M	$1.604M
Prepaid Expenses
Receivables	$1.651M	$1.542M	$1.542M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.016M	$4.186M	$4.186M
YoY Change	-9.83%	-8.86%	-8.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$46.18K	$52.66K	$840.9K
YoY Change	-36.66%	-35.34%	-9.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$62.79K	$62.79K	$62.79K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$911.2K	$986.5K	$986.5K
YoY Change	-9.6%	-9.52%	-9.51%
TOTAL ASSETS
Total Short-Term Assets	$4.016M	$4.186M	$4.186M
Total Long-Term Assets	$911.2K	$986.5K	$986.5K
Total Assets	$4.927M	$5.172M	$5.172M
YoY Change	-9.79%	-8.99%	-8.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.290M	$1.012M	$1.012M
YoY Change	14.99%	-8.14%	-8.14%
Accrued Expenses	$842.0K	$902.0K	$1.319M
YoY Change	6.17%	29.68%	21.36%
Deferred Revenue		$212.6K
YoY Change		229.57%
Short-Term Debt	$204.5K	$201.6K	$204.7K
YoY Change	0.0%	0.0%	-70.94%
Long-Term Debt Due	$3.400K	$3.400K	$3.400K
YoY Change	0.0%	0.0%	0.0%
Total Short-Term Liabilities	$3.158M	$3.002M	$3.002M
YoY Change	8.5%	-11.62%	-11.62%
LONG-TERM LIABILITIES
Long-Term Debt	$152.5K	$153.4K	$153.4K
YoY Change	-4.05%	-1.0%	-1.0%
Other Long-Term Liabilities	$459.2K	$0.00	$538.8K
YoY Change	1023.81%	-100.0%	-19.73%
Total Long-Term Liabilities	$611.7K	$692.2K	$692.2K
YoY Change	-20.95%	-16.21%	-16.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.158M	$3.002M	$3.002M
Total Long-Term Liabilities	$611.7K	$692.2K	$692.2K
Total Liabilities	$3.770M	$3.694M	$3.694M
YoY Change	2.32%	-12.52%	-12.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$69.20M	-$68.90M
YoY Change	0.87%	0.01%
Common Stock	$7.415K	$7.415K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.157M	$1.478M	$1.478M
YoY Change
Total Liabilities & Shareholders Equity	$4.927M	$5.172M	$5.172M
YoY Change	-9.79%	-8.99%	-8.99%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022
OPERATING ACTIVITIES
Net Income	-$320.7K	$50.03K	$18.08K
YoY Change	-201.1%	-72.74%	-134.76%
Depreciation, Depletion And Amortization	$11.49K	$11.49K	$48.43K
YoY Change	-14.61%	-3.28%	8.08%
Cash From Operating Activities	-$310.4K	-$452.8K	-$1.050M
YoY Change	-21.1%	41825.93%	-225.18%
INVESTING ACTIVITIES
Capital Expenditures	-$7.160K	$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$7.155K	$0.00	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net			$2.980K
YoY Change
Cash From Financing Activities	-$1.175K	-1.800K	-$6.931K
YoY Change	-29.34%	91.49%	89.16%
NET CHANGE
Cash From Operating Activities	-$310.4K	-452.8K	-$1.050M
Cash From Investing Activities	-$7.155K	0.000	$0.00
Cash From Financing Activities	-$1.175K	-1.800K	-$6.931K
Net Change In Cash	-$318.7K	-454.6K	-$1.057M
YoY Change	-19.32%	22404.95%	-228.0%
FREE CASH FLOW
Cash From Operating Activities	-$310.4K	-$452.8K	-$1.050M
Capital Expenditures	-$7.160K	$0.00	$0.00
Free Cash Flow	-$303.2K	-$452.8K	-$1.050M
YoY Change		41825.93%	-223.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000862668
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-20127
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7415329	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	35000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	35000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7415329	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7415329	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7415329	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7415329	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2000000	shares
CY2022	us-gaap	Line Of Credit Facility Periodic Payment Interest LineOfCreditFacilityPeriodicPaymentInterest	10000	usd
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2000000	shares
CY2022	dei	City Area Code CityAreaCode	610
CY2022	dei	Local Phone Number LocalPhoneNumber	688-6830
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
	us-gaap	Pension And Other Postretirement Benefit Contributions PensionAndOtherPostretirementBenefitContributions	8491	usd
CY2020Q2	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current And Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent	792000	usd
CY2021	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	758000	usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Entity Registrant Name EntityRegistrantName	Escalon Medical Corp.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	PA
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0272839
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	435 Devon Park Drive, Suite 824
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Wayne
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19087
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q4	dei	Entity Public Float EntityPublicFloat	327167	usd
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7415329	shares
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68900000	usd
CY2022	dei	Auditor Location AuditorLocation	Marlton, New Jersey
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	593869	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1650970	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	256165	usd
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	255920	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1541750	usd
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1081702	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1603955	usd
CY2021Q2	us-gaap	Inventory Net InventoryNet	1416727	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	190043	usd
CY2021Q2	us-gaap	Other Assets Current OtherAssetsCurrent	187357	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	4185782	usd
CY2021Q2	us-gaap	Assets Current AssetsCurrent	4592676	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52660	usd
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	81442	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	788257	usd
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	843559	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	82750	usd
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	102400	usd
CY2022Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	62788	usd
CY2021Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	62789	usd
CY2022Q2	us-gaap	Assets Assets	5172237	usd
CY2021Q2	us-gaap	Assets Assets	5682866	usd
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	201575	usd
CY2021Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	201575	usd
CY2022Q2	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	3401	usd
CY2021Q2	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	3401	usd
CY2022Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	0	usd
CY2021Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	500000	usd
CY2022Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	3105	usd
CY2021Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	2862	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1012451	usd
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1102125	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	901996	usd
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	695553	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	112389	usd
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	112389	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	304737	usd
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	279051	usd
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	332383	usd
CY2021Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	363700	usd
CY2022Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	129961	usd
CY2021Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	136107	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3001998	usd
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3396763	usd
CY2022Q2	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	3888	usd
CY2021Q2	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	7839	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	538794	usd
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	630330	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	40860	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	692222	usd
CY2021Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	826167	usd
CY2022Q2	us-gaap	Liabilities Liabilities	3694220	usd
CY2021Q2	us-gaap	Liabilities Liabilities	4222930	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	645000	usd
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	645000	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	7415	usd
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	7415	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69702043	usd
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69702043	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68876441	usd
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68894522	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1478017	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	1459936	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5172237	usd
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5682866	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10703070	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10471617	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6096169	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6044399	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4085982	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3570433	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	990982	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	890482	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	11173133	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	10505314	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-470063	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-33697	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	506305	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2530	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	245	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	985	usd
CY2022	us-gaap	Interest Expense InterestExpense	18406	usd
CY2021	us-gaap	Interest Expense InterestExpense	21841	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	488144	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18326	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18081	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-52023	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	51600	usd
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	51422	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-33519	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-103445	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7415329	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7415329	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13220202	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7415329	shares
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	1459936	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18081	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1478017	usd
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1511959	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-52023	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	1459936	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18081	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-52023	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	155267	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	10000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	506305	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	48432	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	44812	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	279719	usd
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	274615	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	615315	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-221233	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	187229	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-368303	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2684	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	33164	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-89674	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	341504	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	218373	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	14506	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-290267	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-276833	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-31317	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-152353	usd
CY2022	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-47006	usd
CY2021	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	78105	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1049925	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	838705	usd
CY2022	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	0	usd
CY2021	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	9390	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9390	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3951	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3664	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6931	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3664	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1056856	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	825651	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1906890	usd
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1081239	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	850034	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1906890	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	593869	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1650970	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	256165	usd
CY2021Q2	us-gaap	Restricted Cash RestrictedCash	255920	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	850034	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1906890	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1650970	usd
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	825958	usd
CY2021Q2	us-gaap	Restricted Cash RestrictedCash	255920	usd
CY2020Q2	us-gaap	Restricted Cash RestrictedCash	255281	usd
CY2021	us-gaap	Line Of Credit Facility Periodic Payment Interest LineOfCreditFacilityPeriodicPaymentInterest	10000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1906890	usd
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1081239	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	18406	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	11223	usd
CY2022	esmc	Record Ro Uassets RecordROUassets	224417	usd
CY2021	esmc	Record Ro Uassets RecordROUassets	20200	usd
CY2022	esmc	Record Lease Liabilities RecordLeaseLiabilities	224417	usd
CY2021	esmc	Record Lease Liabilities RecordLeaseLiabilities	20200	usd
CY2022	esmc	Dispose Ro Uassets DisposeROUassets	0	usd
CY2021	esmc	Dispose Ro Uassets DisposeROUassets	9154	usd
CY2022	esmc	Dispose Lease Liabilities DisposeLeaseLiabilities	0	usd
CY2021	esmc	Dispose Lease Liabilities DisposeLeaseLiabilities	9154	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc. The Company dissolved two other inactive entities, Escalon Holdings, Inc. and Escalon IP Holdings, Inc. in a tax-free dissolution under Section 332 of the Internal Revenue Code in the year ended June 30, 2021.<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and have jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) a pandemic. This pandemic has had a significant impact on the global and domestic economy, and has and is likely to continue to impact the operations of the Company. The Company has been assessing the impact of the COVID-19 pandemic on the business, including the impact on the financial condition and results of operations, financial resources, changes in accounting judgment as well as the impact on the supply and demand, etc. The Company is considered an essential business and has been able to maintain operations during the lockdown. The Company applied for and received $500,000 in April 2020 under the Payroll Protection Program ("PPP loan") which will help reverse the negative impact in terms of the liquidity. The Company submitted the loan forgiveness application on August 2, 2021. The PPP loan forgiveness was approved and the full amount and accrued interest was forgiven on August 13, 2021. The Company also received Economic Injury Disaster loan ("EIDL") loan of $150,000. The annual interest rate is 3.75%. The payment term is 30 years and the monthly payment is $731 from July 1, 2021. The Company was spared from the government shutdown during the pandemic. The supply chain challenges could increase the costs of products and numbers of backorders and could adversely affect our results of operations. In February 2022, Russia invaded Ukraine. As military activity proceeds and sanctions, export controls and other measures are imposed by many countries against Russia, Belarus and specific areas of Ukraine, the war is increasingly affecting the global economy and financial markets, as well as exacerbating ongoing economic challenges, including rising inflation and global supply-chain disruption. The Company has operations or activities in countries and regions outside the United States. As a result, its global operations are affected by economic, political and other conditions in the foreign countries in which the Company has business as well as U.S. laws regulating international trade, although the Company has not yet assessed that the war has had a material effect on its financial position or results of operations. The Company will continue to monitor the impacts of the Russia-Ukraine war on macroeconomic conditions and continually assess the effect these matters may have on customer demand, suppliers’ ability to deliver products, cybersecurity risks and its liquidity and access to capital.</span></div> The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”
CY2021	esmc	Pp Ploanamount PPPloanamount	500000	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	138182	usd
CY2021Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	171097	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68900000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	The preparation of financial statements in conformity with accounting principles generally affected in the United States of America Generally Accepted Accounting Principles ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
CY2022	esmc	Maximum Maturity Of Highly Liquid Investments Period MaximumMaturityOfHighlyLiquidInvestmentsPeriod	P90D
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	256000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	4000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	236000	usd
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000	usd
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100480	usd
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	122515	usd
CY2022	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	155267	usd
CY2021	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	10000	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	19398	usd
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	32035	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	236349	usd
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100480	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	1010471	usd
CY2021Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	833105	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	805698	usd
CY2021Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	773451	usd
CY2022Q2	us-gaap	Inventory Gross InventoryGross	1954351	usd
CY2021Q2	us-gaap	Inventory Gross InventoryGross	1777653	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	350396	usd
CY2021Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	360926	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1603955	usd
CY2021Q2	us-gaap	Inventory Net InventoryNet	1416727	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	938644	usd
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	938644	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	885984	usd
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	857202	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52660	usd
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	81442	usd
CY2021Q2	us-gaap	Deferred Revenue DeferredRevenue	364000	usd
CY2020Q2	us-gaap	Deferred Revenue DeferredRevenue	516000	usd
CY2022	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	692000	usd
CY2021	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	772000	usd
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	723000	usd
CY2021	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	924000	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	333000	usd
CY2021Q2	us-gaap	Deferred Revenue DeferredRevenue	364000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	213000	usd
CY2022	us-gaap	Advertising Costs Policy Capitalized Direct Response Advertising AdvertisingCostsPolicyCapitalizedDirectResponseAdvertising	Advertising costs are charged to operations as incurred. Advertising expense for the years ended June 30, 2022 and 2021 was $0 and $4,000. The Company had in-house marketing activities during the year ended June 30, 2022 and 2021.
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18081	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	106220	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-52023	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	51600	usd
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	51422	usd
CY2022	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-33519	usd
CY2021	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-103445	usd
CY2022	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-33519	usd
CY2021	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-103445	usd
CY2022	us-gaap	Convertible Preferred Dividends Net Of Tax ConvertiblePreferredDividendsNetOfTax	51600	usd
CY2021	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	18081	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-103445	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7415329	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7415329	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13220202	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7415329	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	157000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5617873	shares
CY2022Q2	esmc	Finitelivedtangibleassetsaccumulatedimpairment Finitelivedtangibleassetsaccumulatedimpairment	0	usd
CY2022Q2	esmc	Finitelivedtangibleassetsaccumulatedimpairment Finitelivedtangibleassetsaccumulatedimpairment	0	usd
CY2021Q2	esmc	Finitelivedtangibleassetsaccumulatedimpairment Finitelivedtangibleassetsaccumulatedimpairment	0	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-66042	usd
CY2021Q2	esmc	Finitelivedtangibleassetsaccumulatedimpairment Finitelivedtangibleassetsaccumulatedimpairment	0	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	445651	usd
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	464213	usd
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	0	usd
CY2021Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	11506	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	212555	usd
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	64494	usd
CY2022Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	32078	usd
CY2021Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	32078	usd
CY2022Q2	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	100380	usd
CY2021Q2	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	100834	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	111332	usd
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	22428	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	901996	usd
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	695553	usd
CY2022Q2	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.05
CY2022Q2	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	201575	usd
CY2021Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	500000	usd
CY2022Q2	us-gaap	Other Long Term Debt OtherLongTermDebt	82000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	157000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	157000	shares
CY2022Q2	esmc	Share Based Compensation Arrangementby Share Based Payment Award Unvested ShareBasedCompensationArrangementbyShareBasedPaymentAwardUnvested	0	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	157000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.47
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	157000	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.47
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	0	usd
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	0	usd
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	157000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.47
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	157000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.47
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	157000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.47
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	157000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.47
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	157000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	157000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-82615	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	51366	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-23605	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	14676	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	106220	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-66042	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.0000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.0000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2100
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2022Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	57628	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7430299	usd
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7352719	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	0	usd
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	0	usd
CY2021Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	49633	usd
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	21100	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	48969	usd
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	49336	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	73583	usd
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	69432	usd
CY2021Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	65432	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Warranty Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves	6736	usd
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Warranty Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves	6736	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7666848	usd
CY2021Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7564755	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7649471	usd
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7543251	usd
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	17377	usd
CY2021Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	21504	usd
CY2022Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	17377	usd
CY2021Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	21504	usd
CY2022Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	17377	usd
CY2021Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	21504	usd
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7649471	usd
CY2022Q2	us-gaap	Related Party Transaction Due From To Related Party RelatedPartyTransactionDueFromToRelatedParty	645000	usd
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2000000	shares
CY2022	us-gaap	Common Stock Voting Rights CommonStockVotingRights	77.81
CY2022Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	2.15	shares
CY2022	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	4,300,000
CY2022Q2	esmc	Convertible Preferred Stock Percentage Of Outstanding Shares Of Common Stock Upon Conversion ConvertiblePreferredStockPercentageOfOutstandingSharesOfCommonStockUponConversion	0.3670
CY2020Q2	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.0258
CY2022	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	225731	usd
CY2022Q2	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.1129
CY2021	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	174131	usd
CY2021Q2	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.0871
CY2021	us-gaap	Concentration Risk Supplier ConcentrationRiskSupplier	two
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	538794	usd
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	630330	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	337774	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	346302	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	337774	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	346302	usd
CY2022	us-gaap	Short Term Lease Payments ShortTermLeasePayments	334912	usd
CY2021	us-gaap	Short Term Lease Payments ShortTermLeasePayments	335549	usd
CY2022	us-gaap	Short Term Lease Payments ShortTermLeasePayments	334912	usd
CY2021	us-gaap	Short Term Lease Payments ShortTermLeasePayments	335549	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	788257	usd
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	843559	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	304737	usd
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	279051	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	343242	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	350142	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	211215	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	2728	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	907327	usd
CY2022Q2	esmc	Interestportioninthefutureleasepayments Interestportioninthefutureleasepayments	63796	usd
CY2022Q2	esmc	Netpresentvalueofnewleasefuturepayments Netpresentvalueofnewleasefuturepayments	843531	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M9D
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M6D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0565
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0565
CY2022	dei	Auditor Name AuditorName	Friedman LLP
CY2022	dei	Auditor Firm AuditorFirmId	711

Files In Submission

Name	View Source	Status
0000862668-22-000023-index-headers.html	Edgar Link	pending
0000862668-22-000023-index.html	Edgar Link	pending
0000862668-22-000023.txt	Edgar Link	pending
0000862668-22-000023-xbrl.zip	Edgar Link	pending
esmc-20220630_cal.xml	Edgar Link	unprocessable
esmc-20220630.htm	Edgar Link	pending
esmc-20220630.xsd	Edgar Link	pending
esmc_20220630-10kex231.htm	Edgar Link	pending
esmc_20220630-10kex311.htm	Edgar Link	pending
esmc_20220630-10kex321.htm	Edgar Link	pending
esmc_20220630-10kex322.htm	Edgar Link	pending
esmc_20221630-10kex312.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
esmc-20220630_def.xml	Edgar Link	unprocessable
esmc-20220630_pre.xml	Edgar Link	unprocessable
esmc-20220630_lab.xml	Edgar Link	unprocessable
esmc-20220630_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ESMC
ESCALON MEDICAL CORP Stock $esmc

2022 Q3 Form 10-K Financial Statement

#000086266822000023 Filed on September 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESMC ESCALON MEDICAL CORP Stock $esmc

2022 Q3 Form 10-K Financial Statement

#000086266822000023 Filed on September 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESMC
ESCALON MEDICAL CORP Stock $esmc